Doi, Toshihiko http://orcid.org/0000-0003-2042-6829
Boku, Narikazu
Onozawa, Yusuke
Takahashi, Keishiro
Kawaguchi, Osamu
Ohtsu, Atsushi
Funding for this research was provided by:
Sanofi K.K. (Not applicable)
Article History
Received: 28 August 2019
Accepted: 13 December 2019
First Online: 6 January 2020
Compliance with ethical standards
:
: TD received research funding from Eli Lilly, Kyowa Hakko Kirin, MSD, Daiichi Sankyo, Sumitomo Dainippon, Taiho, Novartis, Merck Serono, Janssen, Boehringer Ingelheim, Pfizer, Chugai Pharma, Bristol-Myers Squibb, Abbvie, Quintiles and Eisai, and reports consultancy for Lilly, Kyowa Hakko Kirin, MSD, Daiichi Sankyo, Amgen, Sumitomo Dainippon, Taiho, Novartis, Takeda, Chugai Pharma, Abbvie, Bayer, and Rakuten Medical; NB received research grants from Ono and Taiho, and honorarium from Ono, Taiho, Bristol-Myers Squibb, Eli Lilly and Chugai Pharma; YO has nothing to disclose; KT and OK are employees of Sanofi; AO received a research grant from Bristol-Myers Squibb and reports honorarium from Bristol-Myers Squibb, Ono, Taiho, and Chugai Pharma.
: The study protocol was approved by the Institutional Review Boards at both participating centers. The study was conducted in accordance with the principles laid down by the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments laid down by the World Medical Assemblies, and the ICH guidelines for Good Clinical Practice.
: All patients provided written informed consent prior to enrollment.